Portola Pharmaceuticals   Print Page    Close Window

Keyword Search
2018 | 2017 | 2016 | 2015
March 12, 2018Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening BleedingPrinter Friendly Version
March 12, 2018Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General CounselPrinter Friendly Version
March 06, 2018Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
March 05, 2018Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet AlfaPrinter Friendly Version
February 28, 2018Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
February 20, 2018Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and BetrixabanPrinter Friendly Version
February 15, 2018Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018Printer Friendly Version
January 22, 2018Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18Printer Friendly Version